Avadel Pharmaceuticals plc (AVDL) P/E Ratio History
Deep ValueTrading at -42.4x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2004–2025
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Avadel Pharmaceuticals plc (AVDL) trades at a price-to-earnings ratio of -42.4x, with a stock price of $21.64 and trailing twelve-month earnings per share of $-0.00.
The current P/E is 101% below its 5-year average of 4835.3x. Over the past five years, AVDL's P/E has ranged from a low of 5.2x to a high of 76350.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, AVDL trades at a 292% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, AVDL trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AVDL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AVDL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AVDL P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.8Lowest | 0.66Best | +817%Best | |
| $2B | 40.1 | 5.99 | +14% | |
| $1B | 19.4 | 1.08 | -7% | |
| $8B | 26.8 | 1.17 | -25% | |
| $7B | 10.2 | - | +264% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
AVDL Historical P/E Data (2004–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $15.27 | $0.00 | 76350.0x | +1479% |
| FY2020 Q4 | - | $6.68 | $0.08 | 84.7x | -98% |
| FY2020 Q3 | Sep 30 2020 | $5.04 | $0.20 | 25.7x | -99% |
| FY2020 Q2 | - | $8.08 | $0.16 | 51.9x | -99% |
| FY2018 Q1 | Mar 31 2018 | $7.29 | $0.64 | 11.4x | -100% |
| FY2017 Q4 | Dec 31 2017 | $8.20 | $1.57 | 5.2x | -100% |
| FY2017 Q3 | Sep 30 2017 | $10.50 | $1.92 | 5.5x | -100% |
| FY2017 Q2 | Jun 30 2017 | $11.03 | $0.86 | 12.8x | -100% |
| FY2016 Q3 | Sep 30 2016 | $12.40 | $0.58 | 21.4x | -100% |
| FY2016 Q2 | - | $10.74 | $0.69 | 15.6x | -100% |
| FY2016 Q1 | - | $11.04 | $1.44 | 7.7x | -100% |
| FY2015 Q4 | - | $12.21 | $0.90 | 13.6x | -100% |
| FY2012 Q4 | Dec 31 2012 | $3.03 | $0.22 | 13.5x | -100% |
| FY2005 Q1 | - | $12.94 | $0.21 | 60.7x | -99% |
| FY2004 Q4 | Dec 31 2004 | $19.49 | $0.38 | 50.9x | -99% |
| FY2004 Q3 | - | $14.67 | $0.02 | 635.1x | -87% |
Average P/E for displayed period: 4835.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AVDL — Frequently Asked Questions
Quick answers to the most common questions about buying AVDL stock.
What is AVDL's P/E ratio?
Avadel Pharmaceuticals plc (AVDL) trailing twelve-month P/E ratio is -42.4x, based on TTM diluted EPS of $-0.00. The 5-year average P/E is 4835.3x and the historical range spans 5.2x to 76350.0x.
Is AVDL stock overvalued or undervalued?
AVDL trades at -42.4x P/E, below its 5-year average of 4835.3x. At the 0th percentile of its historical range (5.2x–76350.0x), the stock is priced at a discount to its own history.
Is AVDL stock expensive?
No, AVDL is not expensive on a historical basis. The current P/E of -42.4x is below the 5-year average of 4835.3x and sits at the 0th percentile of its valuation range.
What is AVDL's historical P/E range?
Over the past 5 years, AVDL's P/E ratio has ranged from 5.2x to 76350.0x, with a median of 21.4x and an average of 4835.3x. The current P/E of -42.4x places the stock at the 0th percentile of this range. Full historical data spans 2004–2025.
How does AVDL's P/E compare to the S&P 500?
AVDL trades at -42.4x P/E versus the S&P 500 median of 24.4x. The 274% discount to the market suggests lower growth expectations or perceived higher risk.
How does AVDL's valuation compare to Healthcare peers?
Avadel Pharmaceuticals plc P/E of -42.4x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is AVDL's PEG ratio?
AVDL PEG ratio is N/A, based on a P/E of -42.4x and EPS growth of 74.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AVDL's earnings yield?
AVDL earnings yield is N/A, the inverse of its -42.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.